Territorial Availability: Available through Bertin Technologies only in France
- Correlated keywords
- kits assays measures measurement neutrophils elastases enzymes leukocytes humans blood cytoplasmic cytoplasms azurophilic granules cells cellular stimulation pathogens phorbol myristate acetate PMA excreted excretion exocytosed exocytosis proteins networks of extracellular traps NET proteases released degrades degrading invading immune immunity systems responses expression non-small lung cancers tumors lines U937 HL-60 invasion metastasis insoluble elastins matrix mutations ELA2 genes encoding hereditary neutrophenia inflammatory chronic diseases therapeutics non-fluorescent substrates (Z-Ala-Ala-Ala-Ala)2Rh110 R110 whole regulates regulating releases
- Product Overview:
Neutrophil elastase is stored within cytoplasmic azurophilic granules in the neutrophil and released upon stimulation by pathogens where it acts either as free protein or is associated with networks of extracellular traps (NET). Together with other proteases released from activated neutrophils, neutrophil elastase plays a critical role in degrading invading pathogens and thus provides the earliest line of defense in the immune system. It is thought to play a critical role in tumor invasion and metastasis as well as other inflammatory conditions. Cayman’s Neutrophil Elastase Activity Assay kit is designed to be used to study compounds regulating elastase release in neutrophils. The kit employs a specific non-fluorescent elastase substrate, (Z-Ala-Ala-Ala-Ala)2Rh110, which is selectively cleaved by elastase to yield the highly fluorescent compound R110, which can be analyzed with an excitation wavelength of 485 nm and emission wavelength of 525 nm. Reagents needed to isolate neutrophils from whole blood are included in the kit, as is PMA, which is known to stimulate elastase release from neutrophils.
Cayman Chemical’s mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.
Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.
Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.
Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.
Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009
Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.